The kidney medications transforming kidney care: SGLT2 inhibitors, GLP-1s and finerenone explained

The kidney medications transforming kidney care: SGLT2 inhibitors, GLP-1s and finerenone explained

Episode 164 The Kidney Medications Transforming Kidney Care SGLT2 Inhibitors, GLP-1s & Finerenone Explained Square Artwork

Episode 164

The kidney medications transforming kidney care: SGLT2 inhibitors, GLP-1s and finerenone explained

Could the right medication protect your kidneys, reduce the risk of kidney disease progressing and improve your heart health? Dee Moore speaks with Consultant Nephrologist Professor Alex to explore the medications transforming the treatment of chronic kidney disease: SGLT2 inhibitors, GLP-1 receptor agonists and finerenone. They discuss how these therapies work, who could benefit from them and why they are changing the future of kidney care.

Categories

You might also be interested in:

  • SGLT2 inhibitors

    Information about SGLT2 inhibitors, a type of medication, including benefits, who the medication is suitable for, and potential side effects.

  • GLP-1 medicines and kidney disease: what you need to know

    New GLP-1 medications to manage obesity are generating a lot of media attention due to their potential weight loss and health benefits. On this page we share expert advice about the GLP-1 medications approved for people living with chronic kidney disease (CKD).

  • How undiagnosed kidney reflux led to kidney failure: Noël’s kidney warrior story

    Episode 163

    How undiagnosed kidney reflux led to kidney failure: Noël’s kidney warrior story

    Dee speaks with Noël, who was born with vesicoureteral reflux (VUR), also known as kidney reflux. Noël's condition went undiagnosed until she was seven years old, but by then permanent kidney damage had already occured leading to chronic kidney disease (CKD).